This HTML5 document contains 118 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n14http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n28http://linked.opendata.cz/resource/drugbank/drug/DB01182/identifier/chemspider/
n24http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n27http://linked.opendata.cz/resource/mesh/concept/
n6http://linked.opendata.cz/resource/drugbank/company/
n25http://linked.opendata.cz/resource/drugbank/dosage/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01182/identifier/wikipedia/
n20http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB01182/identifier/pharmgkb/
n4http://linked.opendata.cz/resource/drugbank/drug/DB01182/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
n31http://linked.opendata.cz/resource/drugbank/drug/DB01182/identifier/bindingdb/
n32http://linked.opendata.cz/resource/drugbank/patent/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01182/identifier/pubchem-compound/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/medicinal-product/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01182/identifier/pubchem-substance/
owlhttp://www.w3.org/2002/07/owl#
n26http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n30http://www.drugs.com/cdi/
n29http://linked.opendata.cz/resource/drugbank/drug/DB01182/identifier/drugbank/
n33http://linked.opendata.cz/resource/drugbank/drug/DB01182/identifier/iuphar/
n15http://linked.opendata.cz/resource/drugbank/property/
n19http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01182/identifier/guide-to-pharmacology/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB01182/identifier/national-drug-code-directory/
n22http://linked.opendata.cz/resource/atc/
n21http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01182
rdf:type
n5:Drug
n5:description
An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. [PubChem]
n5:dosage
n25:271B5029-363D-11E5-9242-09173F13E4C5 n25:271B502A-363D-11E5-9242-09173F13E4C5 n25:271B502B-363D-11E5-9242-09173F13E4C5 n25:271B502C-363D-11E5-9242-09173F13E4C5 n25:271B5025-363D-11E5-9242-09173F13E4C5 n25:271B5026-363D-11E5-9242-09173F13E4C5 n25:271B5027-363D-11E5-9242-09173F13E4C5 n25:271B5028-363D-11E5-9242-09173F13E4C5
n5:group
approved
n5:halfLife
2-10 hours
n5:indication
Used to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. Also used for the treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia.
owl:sameAs
n17:DB01182 n20:DB01182
dcterms:title
Propafenone
adms:identifier
n4:C07381 n7:Propafenone n8:2561 n9:4932 n10:46504529 n11:0173-0786-01 n12:PA451131 n28:4763 n29:DB01182 n31:50067133 n33:2561
n5:mechanismOfAction
The electrophysiological effect of propafenone manifests itself in a reduction of upstroke velocity (Phase 0) of the monophasic action potential. In Purkinje fibers, and to a lesser extent myocardial fibers, propafenone reduces the fast inward current carried by sodium ions, which is responsible for the drugs antiarrhythmic actions. Diastolic excitability threshold is increased and effective refractory period prolonged. Propafenone reduces spontaneous automaticity and depresses triggered activity. At very high concentrations in vitro, propafenone can inhibit the slow inward current carried by calcium but this calcium antagonist effect probably does not contribute to antiarrhythmic efficacy.
n5:packager
n6:271B4FFF-363D-11E5-9242-09173F13E4C5 n6:271B5008-363D-11E5-9242-09173F13E4C5 n6:271B5000-363D-11E5-9242-09173F13E4C5 n6:271B4FFE-363D-11E5-9242-09173F13E4C5 n6:271B5007-363D-11E5-9242-09173F13E4C5 n6:271B5011-363D-11E5-9242-09173F13E4C5 n6:271B5012-363D-11E5-9242-09173F13E4C5 n6:271B5002-363D-11E5-9242-09173F13E4C5 n6:271B5003-363D-11E5-9242-09173F13E4C5 n6:271B500F-363D-11E5-9242-09173F13E4C5 n6:271B5010-363D-11E5-9242-09173F13E4C5 n6:271B500D-363D-11E5-9242-09173F13E4C5 n6:271B500E-363D-11E5-9242-09173F13E4C5 n6:271B500B-363D-11E5-9242-09173F13E4C5 n6:271B500C-363D-11E5-9242-09173F13E4C5 n6:271B5009-363D-11E5-9242-09173F13E4C5 n6:271B500A-363D-11E5-9242-09173F13E4C5 n6:271B5005-363D-11E5-9242-09173F13E4C5 n6:271B5006-363D-11E5-9242-09173F13E4C5 n6:271B5001-363D-11E5-9242-09173F13E4C5 n6:271B5004-363D-11E5-9242-09173F13E4C5
n5:patent
n32:5681588
n5:routeOfElimination
Approximately 50% of propafenone metabolites are excreted in the urine following administration of immediate release tablets.
n5:synonym
Propafenona Propafenonum 2-(2'-Hydroxy-3'-propylaminopropoxy)-omega-phenylpropiophenone 1-(2-(2-Hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone
n5:toxicity
Symptoms of propafenone overdose (usually most severe within the first 3 hours) may include convulsions (rarely), heartbeat irregularities, low blood pressure, and sleepiness.
n5:volumeOfDistribution
* 252 L
n21:hasAHFSCode
n24:24-04-04-12
n5:foodInteraction
Always take at the same time in regard to meals. Grapefruit and grapefruit juice should be avoided throughout treatment. Grapefruit can increase serum levels of this product.
n5:proteinBinding
97%
n5:salt
n5:synthesisReference
Helmut Lietz, "Preparation of propafenone." U.S. Patent US4474986, issued May, 1974.
n26:hasConcept
n27:M0017736
foaf:page
n14:propafen.htm n19:ryt1392.shtml n30:propafenone.html
n5:IUPAC-Name
n15:271B5031-363D-11E5-9242-09173F13E4C5
n5:InChI
n15:271B5037-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n15:271B5036-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n15:271B5033-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n15:271B5034-363D-11E5-9242-09173F13E4C5
n5:SMILES
n15:271B5035-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n15:271B502F-363D-11E5-9242-09173F13E4C5 n15:271B5047-363D-11E5-9242-09173F13E4C5
n5:logP
n15:271B502D-363D-11E5-9242-09173F13E4C5 n15:271B5030-363D-11E5-9242-09173F13E4C5 n15:271B5048-363D-11E5-9242-09173F13E4C5
n5:logS
n15:271B502E-363D-11E5-9242-09173F13E4C5
n21:hasATCCode
n22:C01BC03
n5:H-Bond-Acceptor-Count
n15:271B503D-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n15:271B503E-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n15:271B5038-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n15:271B5039-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n15:271B503B-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n15:271B503A-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n15:271B503C-363D-11E5-9242-09173F13E4C5
n5:absorption
Nearly completely absorbed following oral administration (90%). Systemic bioavailability ranges from 5 to 50%, due to significant first-pass metabolism. This wide range in systemic bioavailability is related to two factors: presence of food (food increases bioavailability) and dosage (bioavailability is 3.4% for a 150-mg tablet compared to 10.6% for a 300-mg tablet).
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
54063-53-5
n5:category
n5:containedIn
n18:271B5024-363D-11E5-9242-09173F13E4C5 n18:271B5013-363D-11E5-9242-09173F13E4C5 n18:271B501E-363D-11E5-9242-09173F13E4C5 n18:271B501F-363D-11E5-9242-09173F13E4C5 n18:271B501C-363D-11E5-9242-09173F13E4C5 n18:271B501D-363D-11E5-9242-09173F13E4C5 n18:271B501A-363D-11E5-9242-09173F13E4C5 n18:271B501B-363D-11E5-9242-09173F13E4C5 n18:271B5018-363D-11E5-9242-09173F13E4C5 n18:271B5019-363D-11E5-9242-09173F13E4C5 n18:271B5016-363D-11E5-9242-09173F13E4C5 n18:271B5017-363D-11E5-9242-09173F13E4C5 n18:271B5014-363D-11E5-9242-09173F13E4C5 n18:271B5015-363D-11E5-9242-09173F13E4C5 n18:271B5023-363D-11E5-9242-09173F13E4C5 n18:271B5021-363D-11E5-9242-09173F13E4C5 n18:271B5022-363D-11E5-9242-09173F13E4C5 n18:271B5020-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n15:271B5043-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n15:271B5045-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n15:271B5046-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n15:271B5042-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n15:271B5041-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n15:271B5044-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n15:271B5032-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n15:271B503F-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n15:271B5040-363D-11E5-9242-09173F13E4C5